Polycystic Liver Disease Panel

Test code: GA0201

Is ideal for patients with a clinical suspicion of isolated polycystic liver disease.

All the genes in the panel cause autosomal dominant disease, of which three genes associates to polycystic liver disease (PRKCSH, SEC63 and LRP5) and two genes associates with autosomal dominant polycystic kidney disease (PKD1 and PKD2).

About Polycystic Liver Disease

The Polycystic Liver Disease Panel covers isolated polycystic liver disease (PCLD) and autosomal dominant polycystic kidney disease (ADPKD) where hepatic cysts are present in over 80% of cases as the most frequent extra-renal manifestation. The disease is restricted to the liver in PCLD but ADPKD is a multi-system disorder with polycystic kidneys as the major feature. The most important non-cystic manifestations are vascular abnormalities including intracranial arterial aneurysms, aortic dilatation and dissection. Nearly half of all ADPKD patients have end-stage renal disease (ESRD) by age 60 years. The progressive growth of liver cysts is the most common extrarenal manifestation of ADPKD. The clinical spectrum of ADPKD is wide and variable even within the same family. The implicated gene has prognostic value as the median age at ESRD was 58 years for PKD1 and 79 years for PKD2 related disease. The clinical utility of genetic testing is estimated to be 42% in PCLD (PubMed: 20408955 and 24706814) and over 90% ADPKD (GeneReviews).

Availability

Results in 3-4 weeks

Gene set description

Genes in the Polycystic Liver Disease Panel and their clinical significance

<table>
<thead>
<tr>
<th>Gene</th>
<th>Associated phenotypes</th>
<th>Inheritance</th>
<th>ClinVar</th>
<th>HGMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>GANAB</td>
<td>Polycystic kidney and/or polycystic liver disease 3</td>
<td>AD</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>LRP5*</td>
<td>Van Buchem disease, Osteoporosis-pseudoglioma syndrome, Hyperostosis, endosteal, Osteosclerosis, Exudative vitreoretinopathy, Osteopetrosis late-onset form type 1, LRP5 primary osteoporosis</td>
<td>AD/AR/Digenic</td>
<td>57</td>
<td>196</td>
</tr>
<tr>
<td>PKD1*</td>
<td>Polycystic kidney disease</td>
<td>AD</td>
<td>237</td>
<td>1923</td>
</tr>
<tr>
<td>PKD2</td>
<td>Polycystic kidney disease</td>
<td>AD</td>
<td>55</td>
<td>333</td>
</tr>
<tr>
<td>PRKCSH</td>
<td>Polycystic liver disease</td>
<td>AD</td>
<td>9</td>
<td>28</td>
</tr>
<tr>
<td>SEC63</td>
<td>Polycystic liver disease</td>
<td>AD</td>
<td>8</td>
<td>23</td>
</tr>
</tbody>
</table>

*Some regions of the gene are duplicated in the genome. Read more.*

# The gene has suboptimal coverage (means <90% of the gene’s target nucleotides are covered at >20x with mapping quality score (MQ>20) reads), and/or the gene has exons listed under Test limitations section that are not included in the panel as they are not sufficiently covered with high quality sequence reads.

The sensitivity to detect variants may be limited in genes marked with an asterisk (*) or number sign (#)

Gene refers to the HGNC approved gene symbol; Inheritance refers to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), X-linked dominant (XLD) and X-linked recessive (XLR); ClinVar refers to the number of variants in the gene classified as pathogenic or likely pathogenic in this database (ClinVar); HGMD refers to the number of
variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD). The list of associated, gene specific phenotypes are generated from CGD or Orphanet databases.

Non-coding disease causing variants covered by the panel

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genomic location</th>
<th>HGVS</th>
<th>RefSeq</th>
<th>RS-number</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKD1</td>
<td>Chr16:2140209</td>
<td>c.12445-14T&gt;C</td>
<td>NM_001009944.2</td>
<td></td>
</tr>
<tr>
<td>PKD1</td>
<td>Chr16:2147825</td>
<td>c.10167+25_10167+43delGGCTGGGTGGGGGTCCTG</td>
<td>NM_001009944.2</td>
<td>rs1197421698</td>
</tr>
<tr>
<td>PKD1</td>
<td>Chr16:2152273</td>
<td>c.9202-16G&gt;A</td>
<td>NM_001009944.2</td>
<td>rs1389523126</td>
</tr>
<tr>
<td>PKD2</td>
<td>Chr4:88940551</td>
<td>c.596-59A&gt;G</td>
<td>NM_000297.3</td>
<td>rs750504141</td>
</tr>
</tbody>
</table>

Test Strengths

Exons 1-33 of the PKD1 have multiple segmentally duplicated pseudogenes that reduce sensitivity of NGS diagnostics in general. However, Blueprint Genetics custom assay has good coverage (≥20x) with high mapping rates (mapping quality >40) for 99.5% of the target regions in PKD1 gene. Our validation showed high mean coverage of 199X for the PKD1 gene. Thus, our NGS Panel is not expected to have major limitations in detecting variants in PKD1 gene although clinical validation has not been performed at large scale.

The strengths of this test include:

- CAP accredited laboratory
- CLIA-certified personnel performing clinical testing in a CLIA-certified laboratory
- Powerful sequencing technologies, advanced target enrichment methods and precision bioinformatics pipelines ensure superior analytical performance
- Careful construction of clinically effective and scientifically justified gene panels
- Our Nucleus online portal providing transparent and easy access to quality and performance data at the patient level
- Our publicly available analytic validation demonstrating complete details of test performance
- ~2,000 non-coding disease causing variants in our clinical grade NGS assay for panels (please see 'Non-coding disease causing variants covered by this panel' in the Panel Content section)
- Our rigorous variant classification scheme
- Our systematic clinical interpretation workflow using proprietary software enabling accurate and traceable processing of NGS data
- Our comprehensive clinical statements

Test Limitations

Genes with partial, or whole gene, segmental duplications in the human genome are marked with an asterisk (*) if they overlap with the UCSC pseudogene regions. The technology may have limited sensitivity to detect variants in genes marked with these symbols (please see the Panel content table above).

This test does not detect the following:

- Complex inversions
- Gene conversions
- Balanced translocations
- Mitochondrial DNA variants
- Repeat expansion disorders unless specifically mentioned
- Non-coding variants deeper than ±20 base pairs from exon-intron boundary unless otherwise indicated (please see
above Panel Content / non-coding variants covered by the panel).

This test may not reliably detect the following:
- Low level mosaicism (variant with a minor allele fraction of 14.6% is detected with 90% probability)
- Stretches of mononucleotide repeats
- Indels larger than 50bp
- Single exon deletions or duplications
- Variants within pseudogene regions/duplicated segments

The sensitivity of this test may be reduced if DNA is extracted by a laboratory other than Blueprint Genetics.

For additional information, please refer to the Test performance section and see our Analytic Validation.

Test performance

Our panels are sectioned from our high-quality, clinical grade NGS assay. Please see our sequencing and detection performance table for details regarding our ability to detect different types of alterations (Table).

Assays have been validated for various sample types including EDTA-blood, isolated DNA (excluding from formalin fixed paraffin embedded tissue), saliva and dry blood spots (filter cards). These sample types were selected in order to maximize the likelihood for high-quality DNA yield. The diagnostic yield varies depending on the assay used, referring healthcare professional, hospital and country. Plus analysis increases the likelihood of finding a genetic diagnosis for your patient, as large deletions and duplications cannot be detected using sequence analysis alone. Blueprint Genetics’ Plus Analysis is a combination of both sequencing and deletion/duplication (copy number variant (CNV)) analysis.

Performance of Blueprint Genetics high-quality, clinical grade NGS sequencing assay for panels.

<table>
<thead>
<tr>
<th>Alteration type</th>
<th>Sensitivity % (TP/(TP+FN))</th>
<th>Specificity %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single nucleotide variants</td>
<td>99.89% (99,153/99,266)</td>
<td>&gt;99.9999%</td>
</tr>
<tr>
<td>Insertions, deletions and indels by sequence analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-10 bps</td>
<td>99.2% (7,745/7,806)</td>
<td>&gt;99.9999%</td>
</tr>
<tr>
<td>11-50 bps</td>
<td>99.13% (2,524/2,546)</td>
<td>&gt;99.9999%</td>
</tr>
<tr>
<td>Copy number variants (exon level dels/dups)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 exon level deletion (heterozygous)</td>
<td>100% (20/20)</td>
<td>NA</td>
</tr>
<tr>
<td>1 exon level deletion (homozygous)</td>
<td>100% (5/5)</td>
<td>NA</td>
</tr>
<tr>
<td>1 exon level deletion (het or homo)</td>
<td>100% (25/25)</td>
<td>NA</td>
</tr>
<tr>
<td>2-7 exon level deletion (het or homo)</td>
<td>100% (44/44)</td>
<td>NA</td>
</tr>
<tr>
<td>1-9 exon level duplication (het or homo)</td>
<td>75% (6/8)</td>
<td>NA</td>
</tr>
<tr>
<td>Simulated CNV detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 exons level deletion/duplication</td>
<td>98.7%</td>
<td>100.00%</td>
</tr>
</tbody>
</table>
Size range (0.1-47 Mb) 100% (25/25)

The performance presented above reached by Blueprint Genetics high-quality, clinical grade NGS sequencing assay with the following coverage metrics:

- Mean sequencing depth: 143X
- Nucleotides with >20x sequencing coverage (%): 99.86%

Bioinformatics

The target region for each gene includes coding exons and ±20 base pairs from the exon-intron boundary. In addition, the panel includes non-coding and regulatory variants if listed above (Non-coding variants covered by the panel). Some regions of the gene(s) may be removed from the panel if specifically mentioned in the ‘Test limitations” section above. The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the-art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. Our pipeline is streamlined to maximize sensitivity without sacrificing specificity. We have incorporated a number of reference population databases and mutation databases including, but not limited, to 1000 Genomes Project, gnomAD, ClinVar and HGMD into our clinical interpretation software to make the process effective and efficient. For missense variants, in silico variant prediction tools such as SIFT, PolyPhen, MutationTaster are used to assist with variant classification. Through our online ordering and statement reporting system, Nucleus, ordering providers have access to the details of the analysis, including patient specific sequencing metrics, a gene level coverage plot and a list of regions with <20X sequencing depth if applicable. This reflects our mission to build fully transparent diagnostics where ordering providers can easily visualize the crucial details of the analysis process.

Clinical interpretation

We provide customers with the most comprehensive clinical report available on the market. Clinical interpretation requires a fundamental understanding of clinical genetics and genetic principles. At Blueprint Genetics, our PhD molecular geneticists, medical geneticists and clinical consultants prepare the clinical statement together by evaluating the identified variants in the context of the phenotypic information provided in the requisition form. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals regardless of whether they have formal training in genetics.

Variant classification is the cornerstone of clinical interpretation and resulting patient management decisions. Our classifications follow the Blueprint Genetics Variant Classification Schemes based on the ACMG guideline 2015. Minor modifications were made to increase reproducibility of the variant classification and improve the clinical validity of the report. Our experience with tens of thousands of clinical cases analyzed at our laboratory allowed us to further develop the industry standard.

The final step in the analysis is orthogonal confirmation. Sequence variants classified as pathogenic, likely pathogenic and variants of uncertain significance (VUS) are confirmed using bi-directional Sanger sequencing when they do not meet our stringent NGS quality metrics for a true positive call. Reported heterozygous and homo/hemizygous copy number variations with a size <10 and <3 target exons are confirmed by orthogonal methods such as qPCR if the specific CNV has been seen and confirmed less than three times at Blueprint Genetics.

Our clinical statement includes tables for sequencing and copy number variants that include basic variant information (genomic coordinates, HGVS nomenclature, zygosity, allele frequencies, in silico predictions, OMIM phenotypes and classification of the variant). In addition, the statement includes detailed descriptions of the variant, gene and phenotype(s) including the role of the specific gene in human disease, the mutation profile, information about the gene’s variation in population cohorts and detailed information about related phenotypes. We also provide links to the references, abstracts and variant databases used to help ordering providers further evaluate the reported findings if desired. The conclusion summarizes all of the existing information and provides our rationale for the classification of the variant.

https://blueprintgenetics.com/
Identification of pathogenic or likely pathogenic variants in dominant disorders or their combinations in different alleles in recessive disorders are considered molecular confirmation of the clinical diagnosis. In these cases, family member testing can be used for risk stratification. We do not recommend using variants of uncertain significance (VUS) for family member risk stratification or patient management. Genetic counseling is recommended.

Our interpretation team analyzes millions of variants from thousands of individuals with rare diseases. Our internal database and our understanding of variants and related phenotypes increases with every case analyzed. Our laboratory is therefore well-positioned to re-classify previously reported variants as new information becomes available. If a variant previously reported by Blueprint Genetics is re-classified, our laboratory will issue a follow-up statement to the original ordering health care provider at no additional cost.

# ICD codes

Commonly used ICD-10 codes when ordering the Polycystic Liver Disease Panel

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q44.6</td>
<td>Isolated polycystic liver disease</td>
</tr>
<tr>
<td>Q61.2</td>
<td>Autosomal dominant polycystic kidney disease</td>
</tr>
</tbody>
</table>

# Accepted sample types

- EDTA blood, min. 1 ml
- Purified DNA, min. 3μg*  
- Saliva (Oragene DNA OG-500 kit)

Label the sample tube with your patient’s name, date of birth and the date of sample collection.

Note that we do not accept DNA samples isolated from formalin-fixed paraffin-embedded (FFPE) tissue.

# Resources

- ARPKD/CHF Alliance
- British Liver Trust
- Canadian Liver Foundation
- GeneReviews - Autosomal Dominant Polycystic Kidney Disease
- GeneReviews - Polycystic Kidney Disease
- NORD - Polycystic Liver Disease
- Polycystic Kidney Disease Charity
- Polycystic Kidney Disease Foundation
- Polycystic Liver Disease
- The National Kidney Foundation